

Major Group	Minor Group	Code	Description	Medicare Coverage Criteria: NCD	Medicare Coverage Criteria: LCD/Article	CMS Internet Only Manuals	FDA Criteria	MN Coverage Policy	Comment (Limit, etc)
Cell and Gene Therapy	Car T Cell Therapy	J7330	Carticel	CMS NCD 110.24 Himeric Antigen Receptor (CAR) T-cell Therapy		CMS Benefit Manual Ch15, Section 50	CMS MACI (autologous cultured chondrocytes on procine collagen membrane)	MCP 01	
Cell and Gene Therapy	Car T Cell Therapy	Q2041	Yescarta	CMS NCD 110.24 Himeric Antigen Receptor (CAR) T-cell Therapy		CMS Benefit Manual Ch15, Section 50	FDA Yescarta (axicabtagene ciloleucel)	MCP 02	
Cell and Gene Therapy	Car T Cell Therapy	Q2042	Kymriah (tisagenlecleucel)	CMS NCD 110.24 Himeric Antigen Receptor (CAR) T-cell Therapy		CMS Benefit Manual Ch15, Section 50	FDA Kymriah (tisagenlecleucel)	MCP 03	
Cell and Gene Therapy	Car T Cell Therapy	Q2053	Tecartus (brexucabtagene)	CMS NCD 110.24 Himeric Antigen Receptor (CAR) T-cell Therapy		CMS Benefit Manual Ch15, Section 50	FDA Tecartus (brexucabtagene)	MCP 04	
Cell and Gene Therapy	Car T Cell Therapy	Q2054	Breyanzi (lisocabtagene maraleucel)	CMS NCD 110.24 Himeric Antigen Receptor (CAR) T-cell Therapy		CMS Benefit Manual Ch15, Section 50	FDA Breyanzi (lisocabtagene maraleucel)	MCP 05	
Cell and Gene Therapy	Car T Cell Therapy	Q2055	Abecma (idecabtagene vicleucel)	CMS NCD 110.24 Himeric Antigen Receptor (CAR) T-cell Therapy		CMS Benefit Manual Ch15, Section 50	FDA Abecma (idecabtagene vicleucel)	MCP 06	
Cell and Gene Therapy	Car T Cell Therapy	Q2056	Carvykti (ciltacabtagene autoleucel)	CMS NCD 110.24 Himeric Antigen Receptor (CAR) T-cell Therapy		CMS Benefit Manual Ch15, Section 50	FDA Carvykti (ciltacabtagene autoleucel)	MCP 07	
Cell and Gene Therapy	Car T Cell Therapy	Q2058	Aucatzyl (obecabtagene car pos t)	CMS NCD 110.24 Himeric Antigen Receptor (CAR) T-cell Therapy		CMS Benefit Manual Ch15, Section 50	FDA Aucatzyl (obecabtagene car pos t)	MCP 08	
Cell and Gene Therapy	Cell Therapy	Q2057	Tecelra (afamitresgene autoleucel)			CMS Benefit Manual Ch15, Section 50	FDA Tecelra (afamitresgene autoleucel)	MCP 09	
Cell and Gene Therapy	Cell Therapy	Q2043	Provenge (siuleucel-T)	CMS NCD 110.22 Autologous Cellular Immunotherapy Treatment		CMS Benefit Manual Ch15, Section 50	FDA Provenge (sipuleucel-T)	MCP 10	
Cell and Gene Therapy	Gene Therapy	J1411	Hemgenix (etranacogene dezaparvovec-drlb)			CMS Benefit Manual Ch15, Section 50	FDA Hemgenix (etranacogene dezaparvoved-drlb)	MCP 11	
Cell and Gene Therapy	Gene Therapy	J1412	Roctavian (valoctocogene roxaparvovec-rvox)			CMS Benefit Manual Ch15, Section 50	FDA Roctavian (valoctocogene roxaparvovec-rvox)	MCP 12	
Cell and Gene Therapy	Gene Therapy	J1413	Elevidys (delandistrogene moxeparvovec-rokl)			CMS Benefit Manual Ch15, Section 50	FDA Elevidys (delandistrogene moxeparvovec-rokl)	MCP 13	
Cell and Gene Therapy	Gene Therapy	J1414	Beqvez (fidanacogene elaparvovec-dzkt)			CMS Benefit Manual Ch15, Section 50	FDA Beqvez (fidanacogene elaparvovec-dzkt)	MCP 14	
Cell and Gene Therapy	Gene Therapy	J3387	Skysona (elivaldogene autotemcel)			CMS Benefit Manual Ch15, Section 50	FDA Skysona	MCP 15	
Cell and Gene Therapy	Gene Therapy	J3389	Zevaskyn (Topical administration, prademagene zamikeracel)			CMS Benefit Manual Ch15, Section 50	FDA Zevaskyn	MCP 16	
Cell and Gene Therapy	Gene Therapy	J3391	Lenmeldy (atidarsagene autotemcel)			CMS Benefit Manual Ch15, Section 50	FDA Lenmeldy (atidarsagene autotemcel)	MCP 17	
Cell and Gene Therapy	Gene Therapy	J3392	Casgevy (exagamglogene autotemcel)			CMS Benefit Manual Ch15, Section 50	FDA Casgevy (exagamglogene autotemcel)	MCP 18	
Cell and Gene Therapy	Gene Therapy	J3393	Zynteglo (betibeglogene autotemcel)			CMS Benefit Manual Ch15, Section 50	FDA Zynteglo (betibeglogene autotemcel)	MCP 19	
Cell and Gene Therapy	Gene Therapy	J3394	Lyfgenia (lovotibeglogene autotemcel)			CMS Benefit Manual Ch15, Section 50	FDA Lyfgenia (lovotibeglogene autotemcel)	MCP 20	

Cell and Gene Therapy	Gene Therapy	J3398	Luxturna (voretigene neparvovec)	CMS Benefit Manual Ch15, Section 50	FDA Luxturna (voretigene neparvovec-rzyl)	MCP 21
Cell and Gene Therapy	Gene Therapy	J3399	Zolgensma (onasemnogene abeparvovec)	CMS Benefit Manual Ch15, Section 50	FDA Zolgensma (onasemnogene abeparvovec)	MCP 22
Cell and Gene Therapy	Gene Therapy	J3401	Vyjuvek (beremagene geperpavec-svdt)	CMS Benefit Manual Ch15, Section 50	FDA Vyjuvek (beremagene geperpavec-svdt)	MCP 23
Cell and Gene Therapy	Gene Therapy	J3402	Ryoncil (remestemcel-l-rknd)	CMS Benefit Manual Ch15, Section 50	FDA Ryoncil (remestemcel-l-rknd)	MCP 24
Cell and Gene Therapy	Gene Therapy	J3403	Encelto (revakinagene taroretcel-lwey)	CMS Benefit Manual Ch15, Section 50	FDA Encelto (revakinagene taroretcel-lwey)	MCP 25
Cell and Gene Therapy	Gene Therapy	J9029	Adstiladrin (nadofaragene firadenovec-vncg)	CMS Benefit Manual Ch15, Section 50	FDA Adstiladrin (nadofaragene firadenovec-vncg)	MCP 26
Cell and Gene Therapy	Gene Therapy	J9325	Imlygic (talimogene laherparepvec)	CMS Benefit Manual Ch15, Section 50	FDA Imlygic (talimogene laherparepvec)	MCP 27
Hemophilia	Hemophilia Agents	J7172	Hypmavzi (marstacimab-hncq)	CMS Benefit Manual Ch15, Section 50	FDA Hypmavzi (marstacimab-hncq)	MCP 28
Hemophilia	Hemophilia Agents	J7173	Alhemo (concizumab-mtci)	CMS Benefit Manual Ch15, Section 50	FDA Alhemo (concizumab-mtci)	MCP 29
Hemophilia	Hemophilia Agents	J7174	Qfitlia (fitusiran)	CMS Benefit Manual Ch15, Section 50	FDA Qfitlia (fitusiran)	MCP 30
Hemophilia	Hemophilia Agents	J7182	Factor VIII, (antihemophilic factor, recombinant), (NovoEight)	CMS Benefit Manual Ch15, Section 50	FDA Novoeight (antihemophilic factor, recombinant)	MCP 31
Hemophilia	Hemophilia Agents	J7185	Factor VIII (antihemophilic factor, recombinant) (Xyntha)	CMS Benefit Manual Ch15, Section 50	FDA Xyntha (antihemophilic factor [recombinant])	MCP 32
Hemophilia	Hemophilia Agents	J7186	antihemophilic Factor VIII/von Willebrand factor complex (human)	CMS Benefit Manual Ch15, Section 50	Alphanate (antihemophilic factor/von willebrand factor complex [human])	MCP 33
Hemophilia	Hemophilia Agents	J7187	von Willebrand factor complex (Humate-P)	CMS Benefit Manual Ch15, Section 50	CMS Antihemophilic Factor/von Willebrand Factor Complex (Humate-P)	MCP 34
Hemophilia	Hemophilia Agents	J7188	Factor VIII (antihemophilic factor, recombinant) (Obizur)	CMS Benefit Manual Ch15, Section 50	Obizur [antihemophilic Factor (Recombinant), Porcine Sequence]	MCP 35
Hemophilia	Hemophilia Agents	J7190	Factor VIII (antihemophilic factor, human)	CMS Benefit Manual Ch15, Section 50		MCP 36
Hemophilia	Hemophilia Agents	J7192	Factor VIII (antihemophilic factor, recombinant)	CMS Benefit Manual Ch15, Section 50		MCP 37
Hemophilia	Hemophilia Agents	J7202	Factor IX, albumin fusion protein, (recombinant), Idelvion	CMS Benefit Manual Ch15, Section 50	FDA Idelvion [Coagulation Factor IX (Recombinant), Albumin Fusion Protein]	MCP 38
Hemophilia	Hemophilia Agents	J7204	Factor VIII, antihemophilic factor (recombinant), (Esperoct), glycopegylated-exei	CMS Benefit Manual Ch15, Section 50	FDA Esperoct [antihemophilic factor (recombinant), glycopegylated-exei]	MCP 39
Hemophilia	Hemophilia Agents	J7205	Factor VIII Fc fusion protein (recombinant)	CMS Benefit Manual Ch15, Section 50		MCP 40

Hemophilia	Hemophilia Agents	J7207	Factor VIII, (antihemophilic factor, recombinant), PEGylated	CMS Benefit Manual Ch15, Section 50		MCP 41
Hemophilia	Hemophilia Agents	J7208	Factor VIII, (antihemophilic factor, recombinant), PEGylated-aucl, (Jivi)	CMS Benefit Manual Ch15, Section 50	FDA Jivi [antihemophilic factor (recombinant), PEGylated-aucl]	MCP 42
Hemophilia	Hemophilia Agents	J7209	Factor VIII, (antihemophilic factor, recombinant), (Nuwiq)	CMS Benefit Manual Ch15, Section 50	CMS Nuwiq, Antihemophilic Factor (Recombinant)	MCP 43
Hemophilia	Hemophilia Agents	J7210	Factor VIII, (antihemophilic factor, recombinant), (Afstyla)	CMS Benefit Manual Ch15, Section 50	FDA Afstyla [Antihemophilic Factor (Recombinant), Single Chain]	MCP 44
Hemophilia	Hemophilia Agents	J7211	Factor VIII, (antihemophilic factor, recombinant), (Kovaltry)	CMS Benefit Manual Ch15, Section 50	FDA Kovaltry [Antihemophilic Factor (Recombinant)]	MCP 45
Hemophilia	Hemophilia Agents	J7212	Factor VIIa (antihemophilic factor, recombinant)-jncw (Sevenfact)	CMS Benefit Manual Ch15, Section 50	FDA Sevenfact [coagulation factor VIIa (recombinant)-Jncw]	MCP 46
Hemophilia	Hemophilia Agents	J7213	coagulation factor IX (recombinant), Ixinity	CMS Benefit Manual Ch15, Section 50	FDA Ixinity [coagulation factor IX (recombinant)]	MCP 47
Hormone Treatment	Follicle Stimulating Hormone (FSH)	J3355	Metrodin, Bravelle, Fertilnex (urofollitropin)	CMS Benefit Manual Ch15, Section 50	FDA Bravelle (Urofollitropin)	MCP 48
Hormone Treatment	Follicle Stimulating Hormone (FSH)	S0126	Gonal-F (follitropin alfa)	CMS Benefit Manual Ch15, Section 50	FDA Gonal-F (follitropin alfa for injection)	MCP 49
Hormone Treatment	Follicle Stimulating Hormone (FSH)	S0128	Follistim (follitropin beta)	CMS Benefit Manual Ch15, Section 50	FDA Follistim (follitropin beta)	MCP 50
Hormone Treatment	Gonadotropin Releasing Hormone Agonists (GnRH)	J9226	Histrelin Implant (Supprelin LA)	CMS Benefit Manual Ch15, Section 50	FDA Supprelin LA (histrelin acetate)	MCP 51
Hormone Treatment	Gonadotropin Releasing Hormone Agonists (GnRH)	S0132	Antagon (ganirelix acetate)	CMS Benefit Manual Ch15, Section 50	FDA Ganirelix Acetate Injection	MCP 52
Hormone Treatment	Gonadotropins	J0725	Chorionic gonadotropin	CMS Benefit Manual Ch15, Section 50	Pregnyl (chorionic gonadotropin for injection)	MCP 53
Hormone Treatment	Gonadotropins	S0122	Humegon, Pergonal, Repronex (menotropins)	CMS Benefit Manual Ch15, Section 50	FDA Menopur (metrotropins for injection)	MCP 54
Hormone Treatment	Human Growth Hormone	J2940	Protopin (somatrem)	CMS Benefit Manual Ch15, Section 50		MCP 55
Hormone Treatment	Unclassified Drugs	J3490	Unclassified drugs	CMS Benefit Manual Ch15, Section 50		MCP 56
Hormone Treatment	Unclassified Drugs	J8499	Prescription drug, oral, nonchemotherapeutic, NOS	CMS Benefit Manual Ch15, Section 50		MCP 57
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J0139	Humira (adalimumab)	CMS Benefit Manual Ch15, Section 50	FDA Humira (adalimumab)	MCP 58
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J0172	Aduhelm (aducanumab)	CMS Benefit Manual Ch15, Section 50	FDA Aduhelm (aducanumab)	MCP 59
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J0174	Leqembi (lecanemab-irmb)	CMS NCD 200.3 Monoclonal Antibodies for treatment of Alzheimers CMS Benefit Manual Ch15, Section 50	FDA Leqembi (lecanemab-irmb)	MCP 60
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J0175	Kisunla (donanemab-azbt)	CMS NCD 200.3 Monoclonal Antibodies for treatment of Alzheimers CMS Benefit Manual Ch15, Section 50	FDA Kisunla (donanemab-azbt)	MCP 61
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J0202	Lemtrada (alemtuzumab)	CMS Benefit Manual Ch15, Section 50	FDA Lemtrada (alemtuzumab)	MCP 62

Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J0490	Benlysta (Belimumab)		CMS Benefit Manual Ch15, Section 50	FDA Benlysta (belimumab)	MCP 63
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J0491	Saphnelo (anifrolumab-fnia)		CMS Benefit Manual Ch15, Section 50	FDA Saphnelo (anifrolumab-fnia)	MCP 64
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J0517	Fasenra (benralizumab)		CMS Benefit Manual Ch15, Section 50	FDA Fasenra (benralizumab)	MCP 65
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J0565	Zinplava (Bezlotoxumab)		CMS Benefit Manual Ch15, Section 50	FDA Zinplava (Bezlotoxumab)	MCP 66
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J0584	Crysvita (burosumab-twza)		CMS Benefit Manual Ch15, Section 50	FDA Crysvita (burosumab-twza)	MCP 67
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J0593	Takhzyro (lanadelumab)		CMS Benefit Manual Ch15, Section 50	FDA Takhzyro (lanadelumab)	MCP 68
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J0717	Cimzia (certolizumab)		CMS Benefit Manual Ch15, Section 50	FDA Cimzia (certolizumab-pegol)	MCP 69
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J0791	Adakveo (crizanlizumab-tmca)		CMS Benefit Manual Ch15, Section 50	FDA Adakveo (crizanlizumab-tmca)	MCP 70
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J1299	(eculizumab)	LCD Article A545548 Eculizumab	CMS Benefit Manual Ch15, Section 50	FDA Eculizumab	MCP 71
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J1302	Enjaymo (sutimlimab-jome)		CMS Benefit Manual Ch15, Section 50	FDA Enjaymo (sutimlimab-jome)	MCP 72
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J1303	Ultomiris (ravulizumab-cwvz)		CMS Benefit Manual Ch15, Section 50	FDA Ultomiris (ravulizumab-cwvz)	MCP 73
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J1305	Evkeeza (evinacumab-dgnb)		CMS Benefit Manual Ch15, Section 50	FDA Evkeeza (evinacumab-dgnb)	MCP 74
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J1307	Piasky (crovalimab-akkz)		CMS Benefit Manual Ch15, Section 50	FDA Piasky (crovalimab-akkz)	MCP 75
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J1428	Enbrel (etanercept)		CMS Benefit Manual Ch15, Section 50	FDA Enbrel (etanercept)	MCP 76
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J1602	Simponi (golimumab)		CMS Benefit Manual Ch15, Section 50	FDA Simponi (golimumab)	MCP 77
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J1628	Tremfya (guselkumab)		CMS Benefit Manual Ch15, Section 50	FDA Tremfya (guselkumab)	MCP 78
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J1745	Remicade (infliximab)	CMS Article A52423: Infliximab and Biosimilars	CMS Benefit Manual Ch15, Section 50	FDA Remicade (infliximab)	MCP 79
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J1746	Trogarzo (ibalizumab-uiyk)		CMS Benefit Manual Ch15, Section 50	FDA Trogarzo (ibalizumab-uiyk)	MCP 80
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J1747	Spevigo (spesolimab-sbzo)		CMS Benefit Manual Ch15, Section 50	FDA Spevigo (spesolimab-sbzo)	MCP 81
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J1748	Zymfentra (infliximab-dyyb)		CMS Benefit Manual Ch15, Section 50	FDA Zymfentra (infliximab-dyyb)	MCP 82
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J1823	Uplizna (inebilizumab)		CMS Benefit Manual Ch15, Section 50	FDA Uplizna (inebilizumab)	MCP 83
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J2182	Nucala (mepolizumab)		CMS Benefit Manual Ch15, Section 50	FDA Nucala (mepolizumab)	MCP 84
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J2267	OmvoH (mirikizumab-mrkz)		CMS Benefit Manual Ch15, Section 50	FDA OmvoH (mirikizumab-mrkz)	MCP 85
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J2323	Tysabri (natalizumb)		CMS Benefit Manual Ch15, Section 50	FDA Tysabri (natalizumab)	MCP 86

Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J2326	Spinraza (nusinersen)		CMS Benefit Manual Ch15, Section 50	FDA Spinraza (nusinersen)	MCP 87
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J2327	Skyrizi (risankizumab-rzaa)		CMS Benefit Manual Ch15, Section 50	FDA Skyrizi (risankizumab-rzaa)	MCP 88
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J2329	Briumvi (ublituximab-xiiy)		CMS Benefit Manual Ch15, Section 50	FDA Briumvi (ublituximab-xiiy)	MCP 89
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J2350	Ocrevus (ocrelizumab)		CMS Benefit Manual Ch15, Section 50	FDA Ocrevus (ocrelizumab)	MCP 90
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J2351	(ocrelizumab and hyaluronidase-ocsq)		CMS Benefit Manual Ch15, Section 50	FDA Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq)	MCP 91
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J2356	Tezspire (tezepelumab-ekko)		CMS Benefit Manual Ch15, Section 50	FDA Tezspire (tezepelumab-ekko)	MCP 92
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J2357	Xolair (omalizumab)	LCD Article A52448 Omalizumab	CMS Benefit Manual Ch15, Section 50	FDA Xolair (omalizumab)	MCP 93
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J2786	Cinqair (reslizumab)		CMS Benefit Manual Ch15, Section 50	FDA Cinqair (reslizumab)	MCP 94
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J3031	Ajovy (fremanezumab-vfrm)		CMS Benefit Manual Ch15, Section 50	FDA Ajovy (fremanezumab-vfrm)	MCP 95
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J3032	Vyepti (eptinezumab-jjmr)		CMS Benefit Manual Ch15, Section 50	FDA Vyepti (eptinezumab-jjmr)	MCP 96
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J3111	Evenity (romosozumab-aqqg)		CMS Benefit Manual Ch15, Section 50	FDA Evenity (romosozumab-aqqg)	MCP 97
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J3241	Tepezza (teprotumumab-trbw)		CMS Benefit Manual Ch15, Section 50	FDA Tepezza (teprotumumab-trbw)	MCP 98
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J3245	Ilumya (tildrakizumab)		CMS Benefit Manual Ch15, Section 50	FDA Ilumya (tildrakizumab)	MCP 99
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J3247	Cosentyx (secukinumab)		CMS Benefit Manual Ch15, Section 50	FDA Cosentyx (secukinumab)	MCP 100
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J3262	Actemra (tocilizumab)		CMS Benefit Manual Ch15, Section 50	FDA Actemra (tocilizumab)	MCP 101
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J3357	Stelara (ustekinumab - for subcutaneous injection)	Article A53022 Self-Administered Drug Exclusion List	CMS Benefit Manual Ch15, Section 50	FDA Stelara (ustekinumab)	MCP 102
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J3358	Stelara (ustekinumab - for intervenous injection)		CMS Benefit Manual Ch15, Section 50	FDA Stelara (ustekinumab)	MCP 103
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J3380	Entyvio (vedolizumab)		CMS Benefit Manual Ch15, Section 50	FDA Entyvio (vedolizumab)	MCP 104
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J3590	Kineret (anakinra)		CMS Benefit Manual Ch15, Section 50	FDA Kineret (anakinra)	MCP 105
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J7170	Hemlibra (emicizumab)		CMS Benefit Manual Ch15, Section 50	FDA Hemlibra (emicizumab)	MCP 106
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J9204	Poteligeo (mogamulizumab-kpkc)		CMS Benefit Manual Ch15, Section 50	FDA Poteligeo (mogamulizumab-kpkc)	MCP 107
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J9210	Gamifant (emapalumab)		CMS Benefit Manual Ch15, Section 50	FDA Gamifant (emapalumab)	MCP 108
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J9311	Rituxan (rituximab)		CMS Benefit Manual Ch15, Section 50	FDA Rituxan (rituximab)	MCP 109

Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J9312	Rituxan (rituximab)	LCD L39297 Off-label Use of Rituximab and Rituximab Biosimilars	CMS Benefit Manual Ch15, Section 50	FDA Rituxan (rituximab)	MCP 110
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J9329	Tevimbra (tislelizumab-jsgr)		CMS Benefit Manual Ch15, Section 50	FDA Tevimbra (tislelizumab-jsgr)	MCP 111
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J9333	Rystiggo (rozanolixizumab-noli)		CMS Benefit Manual Ch15, Section 50	FDA Rystiggo (rozanolixizumab-noli)	MCP 112
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J9381	Tzield (teplizumab-mzww)		CMS Benefit Manual Ch15, Section 50	FDA Tzield (teplizumab-mzww)	MCP 113
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5098	Imuldosa (ustekinumab-srlf)		CMS Benefit Manual Ch15, Section 50	FDA Imuldosa (ustekinumab-srlf)	MCP 114
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5099	Steqeyma (ustekinumab-stba)		CMS Benefit Manual Ch15, Section 50	FDA Steqeyma (ustekinumab-stba)	MCP 115
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5100	Yesintek (ustekinumab-kfce)		CMS Benefit Manual Ch15, Section 50	FDA Yesintek (ustekinumab-kfce)	MCP 116
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5121	Avsola (influximab biosimilar)	CMS LCD Article A52423: Infliximab and biosimilars	CMS Benefit Manual Ch15, Section 50	FDA Avsola (infliximab-axxq)	MCP 117
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5133	Tofidence (tocilizumab-bavi)		CMS Benefit Manual Ch15, Section 50	FDA Tofidence (tocilizumab-bavi)	MCP 118
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5134	Tyruko (natalizumab-sztn)		CMS Benefit Manual Ch15, Section 50	FDA Tyruko (natalizumab-sztn)	MCP 119
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5135	Tyenne (tocilizumab-aazg)		CMS Benefit Manual Ch15, Section 50	FDA Tyenne (tocilizumab-aazg)	MCP 120
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5137	Wezlana (ustekinumab-auub)		CMS Benefit Manual Ch15, Section 50	FDA Wezlana (ustekinumab-auub)	MCP 121
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5138	Wezlana (ustekinumab-auub)		CMS Benefit Manual Ch15, Section 50	FDA Wezlana (ustekinumab-auub)	MCP 122
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5140	Hulio (adalimumab-fkjp)		CMS Benefit Manual Ch15, Section 50	FDA Hulio (adalimumab-fkjp)	MCP 123
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5141	Yuflyma (adalimumab-aaty)		CMS Benefit Manual Ch15, Section 50	FDA Yuflyma (adalimumab-aaty)	MCP 124
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5142	Simlandi (adalimumab-ryvk)		CMS Benefit Manual Ch15, Section 50	FDA Simlandi (adalimumab-ryvk)	MCP 125
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5143	Cyltezo (adalimumab-adbm)		CMS Benefit Manual Ch15, Section 50	FDA Cyltezo (adalimumab-adbm)	MCP 126
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5144	Idacio (adalimumab-aacf)		CMS Benefit Manual Ch15, Section 50	FDA Idacio (adalimumab-aacf)	MCP 127
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5145	Abrilada (adalimumab-afzb)		CMS Benefit Manual Ch15, Section 50	FDA Abrilada (adalimumab-afzb)	MCP 128
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5151	Epysqli (eculizumab-aagh)	LCD Article A54548 Eculizumab - aagh Epysqli	CMS Benefit Manual Ch15, Section 50	FDA Epysqli (eculizumab-aagh)	MCP 129
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5152	Bkemv (eculizumab-aeeb)	LCD Article A54548 Eculizumab - aeeb Bkemv	CMS Benefit Manual Ch15, Section 50	Bkemv (eculizumab-aeeb)	MCP 130
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q5154	Omlyclo (omalizumab-igec)	LCD Article A52448 Omalizumab and biosimilar, OMLYCLO	CMS Benefit Manual Ch15, Section 50	FDA Omlyclo (omalizumab-igec)	MCP 131
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q9996	Pyzchiva (ustekinumab-ttwe)		CMS Benefit Manual Ch15, Section 50	FDA Pyzchiva (ustekinumab-ttwe)	MCP 132
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q9997	Pyzchiva (ustekinumab-ttwe)		CMS Benefit Manual Ch15, Section 50	FDA Pyzchiva (ustekinumab-ttwe)	MCP 133

Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q9998	Selarsdi (ustekinumab-aekn)	CMS Benefit Manual Ch15, Section 50	FDA Selarsdi (ustekinumab-aekn)	MCP 134	
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	Q9999	Otulfu (ustekinumab-aauz)	CMS Benefit Manual Ch15, Section 50	FDA Otulfu (ustekinumab-aauz)	MCP 135	
Monoclonal Antibodies	Monoclonal Antibodies - Non-Oncology	J9256	Imaavy (nipocalimab-aahu, 3 mg)	CMS Benefit Manual Ch15, Section 50	FDA Imaavy (nipocalimab-aahu)	MCP 136	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9308	Cyramza (ramucirumab)	CMS Benefit Manual Ch15, Section 50	FDA Cyramza (ramucirumab)	MCP 137	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J1246	Unituxin (dinutuximab)	CMS Benefit Manual Ch15, Section 50	FDA Unituxin (dinutuximab)	MCP 138	Code J1246 is no longer active and is not in Encoder. Use most appropriate unclassified drug code
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J1323	Elrexfio (elranatamab-bcmm)	CMS Benefit Manual Ch15, Section 50	FDA Elrexfio (elranatamab-bcmm)	MCP 139	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J1326	(zolbetuximab)	CMS Benefit Manual Ch15, Section 50	FDA Vyloy (zolbetuximab-clzb)	MCP 140	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J2277	Aphexda (motixafortide)	CMS Benefit Manual Ch15, Section 50	FDA Aphexda (motixafortide)	MCP 141	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J3055	Talvey (talquetamab-tgvs)	CMS Benefit Manual Ch15, Section 50	FDA Talvey (talquetamab-tgvs)	MCP 142	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J3263	Loqtorzi (toripalimab-tpzi)	CMS Benefit Manual Ch15, Section 50	FDA Loqtorzi (toripalimab-tpzi)	MCP 143	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9011	Datroway (datopotamab deruxtecan-dlnk)	CMS Benefit Manual Ch15, Section 50	FDA Datroway (datopotamab deruxtecan-dlnk)	MCP 144	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9023	Bavencio (Avelumab)	CMS Benefit Manual Ch15, Section 50	FDA Bavencio (avelumab)	MCP 145	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9024	Tecentriq Hybreza (atezolizumab, 5 mg and hyaluronidase-tqjs)	CMS Benefit Manual Ch15, Section 50	FDA Tecentriq Hybreza (atezolizumab & hyaluronidase - tqjs)	MCP 146	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9026	Imdelltra (tarlatamab-dlle)	CMS Benefit Manual Ch15, Section 50	FDA Imdelltra (tarlatamab-dlle)	MCP 147	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9028	Anktiva (nogapendekin alfa inbakicept-pmln)	CMS Benefit Manual Ch15, Section 50	FDA Anktiva (nogapendekin alfa inbakicept-pmln)	MCP 148	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9042	Adcetris (brentuximab vedotin)	CMS Benefit Manual Ch15, Section 50	FDA Adcetris (brentuximab vendotin)	MCP 149	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9063	Elahere (mirvetuximab soravtansine-gynx)	CMS Benefit Manual Ch15, Section 50	FDA Elahere (mirvetuximab soravtansine-gynx)	MCP 150	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9119	Libtayo (cemiplimab)	CMS Benefit Manual Ch15, Section 50	FDA Libtayo (cemiplimab-rwlc)	MCP 151	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9144	Darzalex Faspro (daratumumab/hyaluronidase)	CMS Benefit Manual Ch15, Section 50	FDA Darzalex Faspro (daratumumab and hyaluronidase-fihj)	MCP 152	
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9145	Darzalex (Daratumumab)	CMS Benefit Manual Ch15, Section 50	FDA Darzalex (daratumumab)	MCP 153	

Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9161	denileukin diftotox-cxdl	CMS Benefit Manual Ch15, Section 50	FDA Lymphir (denileukin diftotox-cxdl)	MCP 154
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9173	Imfinzi (durvalumab)	CMS Benefit Manual Ch15, Section 50	FDA Imfinzi (durvalumab)	MCP 155
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9177	Padcev (enfortumab vedotin)	CMS Benefit Manual Ch15, Section 50	FDA Padcev (enfortumab vedotin-ejfv)	MCP 156
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9203	Mylotarg (Gemtuzumab Ozogamicin)	CMS Benefit Manual Ch15, Section 50	FDA Mylotarg (gemtuzumab ozogamicin)	MCP 157
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9228	Yervoy (ipilimumab)	CMS Benefit Manual Ch15, Section 50	FDA Yervoy (ipilimumab)	MCP 158
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9229	Besponsa (inotuzumab ozogamicin)	CMS Benefit Manual Ch15, Section 50	FDA Besponsa (inotuzumab ozogamicin)	MCP 159
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9271	Keytruda (pembrolizumab)	CMS Benefit Manual Ch15, Section 50	FDA Keytruda (pembrolizumab)	MCP 160
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9272	Jemperli (dostarlimab-gxly)	CMS Benefit Manual Ch15, Section 50	FDA Jemperli (dostarlimab-gxly)	MCP 161
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9273	Tivdak (Tisotumab)	CMS Benefit Manual Ch15, Section 50	FDA Tivdak (tisotumab vedotin-tftv)	MCP 162
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9275	Unloxcyt (cosibelimab-ipdl)	CMS Benefit Manual Ch15, Section 50	FDA Unloxcyt (cosibelimab-ipdl)	MCP 163
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9276	Ziihera (zanidatamab)	CMS Benefit Manual Ch15, Section 50	FDA Ziihera (Zanidatamab-hrii)	MCP 164
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9286	Columvi (glofitamab-gxbm)	CMS Benefit Manual Ch15, Section 50	FDA Columvi (glofitamab-gxbm)	MCP 165
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9289	Opdivo Qvantig (nivolumab and haluronidase-nvhy)	CMS Benefit Manual Ch15, Section 50	FDA Opdivo Qvantig (nivolumab and haluronidase-nvhy)	MCP 166
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9298	Opdualag (nivolumab and relatlimab-rmbw)	CMS Benefit Manual Ch15, Section 50	FDA Opdulag (nivolumab & relatlimab-rmbw)	MCP 167
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9299	Opdivo (nivolumab)	CMS Benefit Manual Ch15, Section 50	FDA Opdivo (nivolumab)	MCP 168
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9306	Perjeta (pertuzumab)	CMS Benefit Manual Ch15, Section 50	FDA Perjeta (pertuzumab)	MCP 169
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9313	Lumoxiti (moxetumomab pasudotoc-tdfk)	CMS Benefit Manual Ch15, Section 50	FDA Lumoxiti (moxetumomab pasudotox-tdfk)	MCP 170
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9316	Phesgo (pertuzumab, trastuzumab, hyaluronidase)	CMS Benefit Manual Ch15, Section 50	FDA Phesgo (pertuzumab, trastuzumab, & hyaluronidase-zzxf)	MCP 171
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9317	Trodelyv (sacituzumab govitecan-hziy)	CMS Benefit Manual Ch15, Section 50	FDA Trodelvy (sacituzumab govitecan-hziy)	MCP 172
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9321	Epkinly (epcoritamab-bysp)	CMS Benefit Manual Ch15, Section 50	FDA Epkinly (epcoritamab-bysp)	MCP 173
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9345	Zynyz (retifanlimab-dlwr)	CMS Benefit Manual Ch15, Section 50	FDA Zynyz (retifanlimab-dlwr)	MCP 174
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9347	Imjudo (tremelimumab-actl)	CMS Benefit Manual Ch15, Section 50	FDA Imjudo (tremelimumab-actl)	MCP 175

Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9348	Danyelza (naxitamab-gqgk)		CMS Benefit Manual Ch15, Section 50	FDA Danyelza (naxitamab-gqgk)	MCP 176
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9349	Monjuvi (tafasitamab-cxix)		CMS Benefit Manual Ch15, Section 50	FDA Monjuvi (tafasitamab-cxix)	MCP 177
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9350	Lunsumo (mosunetuzumab-axgb)		CMS Benefit Manual Ch15, Section 50	FDA Lunsumio (mosunetuzumab-axgb)	MCP 178
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9353	Margenza (margetuximab-cmkb)		CMS Benefit Manual Ch15, Section 50	FDA Margenza (margetuximab-cmkb)	MCP 179
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9354	Kadcyla (ado-trastuzumab)		CMS Benefit Manual Ch15, Section 50	FDA Kadcyla (ado-trastuzumab emtansine)	MCP 180
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9355	Herceptin (trastuzumab)		CMS Benefit Manual Ch15, Section 50	FDA Herceptin (trastuzumab)	MCP 181
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9356	Herceptin (trastuzumab)		CMS Benefit Manual Ch15, Section 50	FDA Herceptin Hylecta (trastruzumab & hyaluronidase-oysk)	MCP 182
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9380	Tecvayli (teclistamab-cqyv)		CMS Benefit Manual Ch15, Section 50	FDA Tecvayli (teclistamab-cqyv)	MCP 183
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9382	Bizengri (zenocutuzumab-zbco)		CMS Benefit Manual Ch15, Section 50	FDA Bizengri (zenocutuzumab-zbco)	MCP 184
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	Q5116	Herceptin (trastuzumab)		CMS Benefit Manual Ch15, Section 50	FDA Trazimera (trastuzumab-qyyp)	MCP 185
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	Q5117	Herceptin (trastuzumab)		CMS Benefit Manual Ch15, Section 50	FDA kanjinti (trastuzumab-anns)	MCP 186
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	Q5119	Ruxience (rituximabpvvr)	LCD - Off-Label Use of Rituximab & Rituximab Biosimilars L39297	CMS Benefit Manual Ch15, Section 50	FDA Ruxience (rituximab-pvvr)	MCP 187
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	Q5123	Riabni (rituximab-arrx biosimilar)	LCD - Off-Label Use of Rituximab & Rituximab Biosimilars L39297	CMS Benefit Manual Ch15, Section 50	FDA Riabni (rituximab-arrx)	MCP 188
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	Q5129	Vegzelma (bevacizumab-adcd)	CMS Article A52370 Bevacizumab & biosimilars	CMS Benefit Manual Ch15, Section 50	FDA Vegzelma (bevacizumab-abcd)	MCP 189
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	Q5160	Jobevne (bevacizumab-nwgd)		CMS Benefit Manual Ch15, Section 50		MCP 190
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	Q5146	Hercessi (trastuzumab-strf)		CMS Benefit Manual Ch15, Section 50	FDA Hercessi (trastuzumab-strf)	MCP 191
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	Q5148	Nypozi (filgrastim-txid)		CMS Benefit Manual Ch15, Section 50	FDA Nypozi (filgrastim-txid)	MCP 192
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	J9326	Emrelis (telisotuzumab vedotin-tllv)		CMS Benefit Manual Ch15, Section 50	FDA Emrelis (telisotuzumab vedotin-tllv)	MCP 193
Monoclonal Antibodies	Monoclonal Antibodies - Oncology	C9307	Lynozyfic (linvoseltamab-gcpt)		CMS Benefit Manual Ch15, Section 50		MCP 194
Neurotoxins	Botulinums	J0585	Botox (onabotulinumtoxinA)	LCD L33646 Botulinum Toxins	CMS Benefit Manual Ch15, Section 50	FDA onabotulinumtoxinA	MCP 195
Neurotoxins	Botulinums	J0586	Dysport (abobotulinumtoxinA)	LCD L33646 Botulinum Toxins	CMS Benefit Manual Ch15, Section 50	FDA abobotulinumtoxinA	MCP 196
Neurotoxins	Botulinums	J0587	Myobloc (rimabotulinumtoxinB)	LCD L33646 Botulinum Toxins	CMS Benefit Manual Ch15, Section 50	FDA rimabotulinumtoxinB	MCP 197
Neurotoxins	Botulinums	J0588	Xeomin (incobotulinumtoxinA)	LCD L33646 Botulinum Toxins	CMS Benefit Manual Ch15, Section 50	FDA incobotulinumtoxinA	MCP 198
Neurotoxins	Botulinums	J0589	Daxxify (daxibotulinumtoxina-lanm)	LCD L33646 Botulinum Toxins	CMS Benefit Manual Ch15, Section 50	FDA daxibotulinumtoxina-lanm	MCP 199
Oncology	Antineoplastic Agents	A9607	Pluvicto (lutetium LU 177)		CMS Benefit Manual Ch15, Section 50	FDA Pluvicto (lutetium LU 177)	MCP 200

Oncology	Antineoplastic Agents	J9021	Rylaze (asparaginase recombinant)		CMS Benefit Manual Ch15, Section 50	FDA Rylaze (asparaginase recombinant)	MCP 201
Oncology	Antineoplastic Agents	J9036	Belrapzo		CMS Benefit Manual Ch15, Section 50	FDA Belrapzo (bendamustine hydrochloride)	MCP 202
Oncology	Antineoplastic Agents	J9061	Rybrevant (amivantamab-vmjw)		CMS Benefit Manual Ch15, Section 50	FDA Rybrevant (amivantamab-vmjw)	MCP 203
Oncology	Antineoplastic Agents	J9064	Sandoz (cabazitaxel)		CMS Benefit Manual Ch15, Section 50	FDA Cabazitaxel	MCP 204
Oncology	Antineoplastic Agents	J9118	Asparlas (calaspargase pegol-mknl)		CMS Benefit Manual Ch15, Section 50	FDA Asparlas (calaspargase pegol-mknl)	MCP 205
Oncology	Antineoplastic Agents	J9198	Infugem (gemcitabine)		CMS Benefit Manual Ch15, Section 50	FDA Infugem (gemcitabine)	MCP 206
Oncology	Antineoplastic Agents	J9205	Irinotecan Liposome		CMS Benefit Manual Ch15, Section 50	FDA Onivyde (Irinotecan Liposome)	MCP 207
Oncology	Antineoplastic Agents	J9223	Zepzelca (lurbinectedin)		CMS Benefit Manual Ch15, Section 50	FDA Zepzelca (lurbinectedin)	MCP 208
Oncology	Antineoplastic Agents	J9246	Evomela (melphalan)		CMS Benefit Manual Ch15, Section 50	FDA Evomela (melphalan)	MCP 209
Oncology	Antineoplastic Agents	J9269	Elzonris (tagraxofusp-erza)		CMS Benefit Manual Ch15, Section 50	FDA Elzonris (tagraxofusp-erza)	MCP 210
Oncology	Antineoplastic Agents	J9274	Kimtrak (tebentafuso-tebn)		CMS Benefit Manual Ch15, Section 50	FDA Kimtrak (tebentafuso-tebn)	MCP 211
Oncology	Antineoplastic Agents	J9314	Istodax (Romidepsin)		CMS Benefit Manual Ch15, Section 50	FDA Istodax (Romidepsin)	MCP 212
Oncology	Antineoplastic Agents	J9352	Yondelis (trabectedin)		CMS Benefit Manual Ch15, Section 50	FDA Yondelis (trabectedin)	MCP 213
Oncology	Antineoplastic Agents	J9358	Enhertu (fam-trastuzumab deruxtecan-nxki)		CMS Benefit Manual Ch15, Section 50	FDA Enhertu (fam-trastuzumab deruxtecan-nxki)	MCP 214
Oncology	Antineoplastic Agents	J9359	Zynlonta (Loncastuximab tesirine)		CMS Benefit Manual Ch15, Section 50	FDA Zynlonta (Loncastuximab tesirine)	MCP 215
Oncology	Other Drugs/treatments	A9513	Lutathera (Lutetium LU 177 Dotatate)		CMS Benefit Manual Ch15, Section 50	FDA Lutathera (Lutetium LU 177 Dotatate)	MCP 216
Ophthalmology	Ophthalmics	J0179	Beovu (brolucizumab)	LCD Article A52451 Brolucizumab-dblj	CMS Benefit Manual Ch15, Section 50	FDA Beovu (brolucizumab)	MCP 217
Ophthalmology	Ophthalmics	J1097	Phenylephrine/Ketorolac solution		CMS Benefit Manual Ch15, Section 50	FDA Phenylephrine/Ketorolac solution	MCP 218
Ophthalmology	Ophthalmics	J2777	Vabysmo (faricimab-svoa)	LCD Article A52451 Faricimab-svoa	CMS Benefit Manual Ch15, Section 50	FDA Vabysmo (faricimab-svoa)	MCP 219
Ophthalmology	Ophthalmics	J2779	Susvimo (ranibizumab) Implant	CMS Article A52451 Ranibizumab and biosimilars	CMS Benefit Manual Ch15, Section 50	FDA Susvimo (ranibizumab) Implant	MCP 220
Ophthalmology	Ophthalmics	J2781	Syfovre (pegcetacoplan)		CMS Benefit Manual Ch15, Section 50	FDA Syfovre (pegcetacoplan)	MCP 221
Ophthalmology	Ophthalmics	J2782	Izervay (avacincaptad pegol)		CMS Benefit Manual Ch15, Section 50	FDA Izervay (avacincaptad pegol)	MCP 222
Ophthalmology	Ophthalmics	J7314	Yutiq (fluocinolone) intravitreal implant		CMS Benefit Manual Ch15, Section 50	FDA Yutiq (fluocinolone) intravitreal implant	MCP 223
Ophthalmology	Ophthalmics	J7351	Bimatoprost Intracameral Implant		CMS Benefit Manual Ch15, Section 50	FDA Bimatoprost Intracameral Implant	MCP 224
Ophthalmology	Ophthalmics	J7355	Travoprost, intracameral implant		CMS Benefit Manual Ch15, Section 50	FDA Travoprost	MCP 225
Ophthalmology	Ophthalmics	Q5124	Byooviz (Ranibizumab-nuna (biosimilar))	Article A53022 Self-Administered Drug Exclusion List	CMS Benefit Manual Ch15, Section 50	FDA Byooviz (Ranibizumab-nuna (biosimilar))	MCP 226
Other	Antisense Oligonucleotide (AO)	J1304	Qalsody (tofersen)		CMS Benefit Manual Ch15, Section 50	FDA Qalsody (tofersen)	MCP 227

Other	Antisense Oligonucleotide (AO)	J1426	Amondys 45 (casimersen)		CMS Benefit Manual Ch15, Section 50	FDA Amondys 45 (casimersen)	MCP 228	
Other	Antisense Oligonucleotide (AO)	J1427	Viltepso (viltolarsen)		CMS Benefit Manual Ch15, Section 50	FDA Viltepso (viltolarsen)	MCP 229	
Other	Antisense Oligonucleotide (AO)	J1428	Exondys		CMS Benefit Manual Ch15, Section 50	FDA Exondys	MCP 230	
Other	Cosmetic treatments	J0591	Kybella (deoxycholic acid)		CMS Benefit Manual Ch15, Section 50	FDA Kybella (deoxycholic acid)	MCP 231	
Other	Cosmetic treatments	Q2028	Sculptra	CMS NCD 250.5 Dermal Injections for Treatment of Facial Lipodystrophy Syndrome	CMS Benefit Manual Ch15, Section 50	FDA Sculptra	MCP 232	
Other	Enzyme Replacement Therapy	J0218	Xenpozyme (olipudase alfa-rpcp)		CMS Benefit Manual Ch15, Section 50	FDA Xenpozyme (olipudase alfa-rpcp)	MCP 233	
Other	Enzyme Replacement Therapy	J0219	Nexviazyme (avalglucosidase alfa-ngpt)		CMS Benefit Manual Ch15, Section 50	FDA Nexviazyme (avalglucosidase alfa-ngpt)	MCP 234	
Other	Enzyme Replacement Therapy	J0567	Brineura (cerliponase alfa)		CMS Benefit Manual Ch15, Section 50	FDA Brineura (cerliponase alfa)	MCP 235	
Other	Enzyme Replacement Therapy	J2508	Elfabrio (pegunigalsidase alfa-iwxj)		CMS Benefit Manual Ch15, Section 50	FDA Elfabrio (pegunigalsidase alfa-iwxj)	MCP 236	
Other	Enzyme Replacement Therapy	J7171	Adzynma (apadamtase alfa)		CMS Benefit Manual Ch15, Section 50	FDA Adzynma (ADAMTS13, recombinant-krhn)	MCP 237	
Other	Genetic Disorder Agents	J0217	Lamzede (velmanase alfa-tycv)		CMS Benefit Manual Ch15, Section 50	FDA Lamzede (velmanase alfa-tycv)	MCP 238	
Other	Genetic Disorder Agents	J1429	Vyondys (golodirsen)		CMS Benefit Manual Ch15, Section 50	FDA Vyondys (golodirsen)	MCP 239	
Other	Gout Treatment	J2507	Krystexxa (pegloticase)		CMS Benefit Manual Ch15, Section 50	FDA Krystexxa (pegloticase)	MCP 240	
Other	Hereditary Angioedema Agents	J0596	C1 esterase inhibitor (recombinant), Ruconest		CMS Benefit Manual Ch15, Section 50	FDA Ruconest (C1 esterase inhibitor [recombinant])	MCP 241	
Other	Hereditary Angioedema Agents	J0597	C1 esterase inhibitor (human), Berinert		CMS Benefit Manual Ch15, Section 50	FDA Berinert [C1 Esterase Inhibitor (human)]	MCP 242	
Other	Hereditary Angioedema Agents	J0598	C1 esterase inhibitor (human), Cinryze		CMS Benefit Manual Ch15, Section 50	FDA Cinrynze (C1 Esterase Inhibitor [human])	MCP 243	
Other	Hereditary Angioedema Agents	J0599	C1 esterase inhibitor (human), (Haegarda)		CMS Benefit Manual Ch15, Section 50	FDA Haegarda (C1 Esterase Inhibitor subcutaneous [human])	MCP 244	
Other	Immunomodulators	J0129	Orencia (abatacept)		CMS Benefit Manual Ch15, Section 50	FDA Orencia (abatacept)	MCP 245	
Other	Kinase Inhibitor	J9057	Aliqopa (copanlisib)		CMS Benefit Manual Ch15, Section 50	FDA Aliqopa (copanlisib)	MCP 246	
Other	Miscellaneous Agents	J0222	Onpattro (patisiran)		CMS Benefit Manual Ch15, Section 50	FDA Onpattro (patisiran)	MCP 247	
Other	Miscellaneous Agents	J0223	Givlaari (givosiran)		CMS Benefit Manual Ch15, Section 50	FDA Givlaari (givosiran)	MCP 248	
Other	Miscellaneous Agents	J0224	Oxlumo (lumasiran)		CMS Benefit Manual Ch15, Section 50	FDA Oxlumo (lumasiran)	MCP 249	
Other	Miscellaneous Agents	J0225	Amvuttra (vutrisiran)		CMS Benefit Manual Ch15, Section 50	FDA Amvuttra (vutrisiran)	MCP 250	
Other	Miscellaneous Agents	J7352	Scenesse (afamelanotide implant)		CMS Benefit Manual Ch15, Section 50	FDA Scenesse (afamelanotide)	MCP 251	
Other	Miscellaneous Agents	J9332	Vyvgart (efgartigimod)		CMS Benefit Manual Ch15, Section 50	FDA Vyvgart (efgartigimod alfa-fcab)	MCP 252	
Other	Unclassified Drugs	C9399	Unclassified drugs or biologicals		CMS Benefit Manual Ch15, Section 50		MCP 253	PA only required if billed charges above \$1000
Other	Unclassified Drugs	J3490	Unclassified Drugs	See CMS for specific drug information	CMS Benefit Manual Ch15, Section 50		MCP 254	PA only required if billed charges above \$1000

Other	Unclassified Drugs	J3535	Drug administered through a metered dose inhaler		CMS Benefit Manual Ch15, Section 50	MCP 255	PA only required if billed charges above \$1000
Other	Unclassified Drugs	J3590	Unclassified Biologics	See CMS for specific drug information	CMS Benefit Manual Ch15, Section 50	MCP 256	PA only required if billed charges above \$1000
Other	Unclassified Drugs	J7599	Immunosuppressive drug, not otherwise classified		CMS Benefit Manual Ch15, Section 50	MCP 257	PA only required if billed charges above \$1000
Other	Unclassified Drugs	J7699	NOC drugs, inhalation solution administered through DME		CMS Benefit Manual Ch15, Section 50	MCP 258	PA only required if billed charges above \$1000
Other	Unclassified Drugs	J7799	NOC drugs, other than inhalation drugs, administered through DME		CMS Benefit Manual Ch15, Section 50	MCP 259	PA only required if billed charges above \$1000
Other	Unclassified Drugs	J7999	Compounded drug, not otherwise classified	CMS Article A53021: Self-Administered Drug Exclusion List	CMS Benefit Manual Ch15, Section 50	MCP 260	PA only required if billed charges above \$1000
Other	Unclassified Drugs	J8498	Antiemetic drug, rectal/suppository, not otherwise specified		CMS Benefit Manual Ch15, Section 50	MCP 261	PA only required if billed charges above \$1000
Other	Unclassified Drugs	J8499	Prescription drug, oral, nonchemotherapeutic, NOS		CMS Benefit Manual Ch15, Section 50	MCP 262	PA only required if billed charges above \$1000
Other	Unclassified Drugs	J8597	Antiemetic drug, oral, not otherwise specified		CMS Benefit Manual Ch15, Section 50	MCP 263	PA only required if billed charges above \$1000
Other	Unclassified Drugs	J8999	Prescription drug, oral, chemotherapeutic, NOS		CMS Benefit Manual Ch15, Section 50	MCP 264	PA only required if billed charges above \$1000
Other	Unclassified Drugs	J9999	Not otherwise classified, antineoplastic drugs		CMS Benefit Manual Ch15, Section 50	MCP 265	PA only required if billed charges above \$1000
Other	Unclassified Drugs	Q4082	Drug or biological, not otherwise classified, Part B drug competitive acquisition program (CAP)		CMS Benefit Manual Ch15, Section 50	MCP 266	PA only required if billed charges above \$1000